Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

66.90 +2.45 (+3.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,643,328
Open 66.46
Bid (Size) 66.58 (1)
Ask (Size) 66.99 (1)
Prev. Close 64.45
Today's Range 65.75 - 66.93
52wk Range 53.63 - 71.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
What Are Whales Doing With AstraZeneca
Someone with a lot of money to spend has taken a bearish stance on AstraZeneca (NASDAQ:AZN). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
AstraZeneca's ALXN1840 Shows Promising Action Against Copper Metabolism Disorder
 
Via Benzinga

Performance

YTD
+14.73%
+14.73%
1 Month
+0.38%
+0.38%
3 Month
+1.33%
+1.33%
6 Month
+16.07%
+16.07%
1 Year
+15.38%
+15.38%

More News

Read More
ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community
From Alexion
Via Business Wire
Short Volatility Alert: AstraZeneca PLC
Via Benzinga
7 Blue-Chip Stocks to Buy and Hold for the Long-Haul
Via InvestorPlace
Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money
Via InvestorPlace
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Via Benzinga
AstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial
Via Benzinga
PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st-line Metastatic Castration-resistant Prostate Cancer Published in New England Journal of Medicine Evidence
From AstraZeneca
Via Business Wire
Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
From AstraZeneca
Via Business Wire
Dow Jones Erased Gains Late in the Day, as Investors Continued to Consider Fears About Sluggish Economic Is Growth.
Via Best Stocks
Topics Stocks
Exposures US Equities
Why Mereo BioPharma Shares Are Jumping Today
Via Benzinga
Dow Jones Today: Investors Flee The Markets On The Belief That The Federal Reserve Would Choose For The First Three-quarter Point Hike
Via Best Stocks
Topics Economy Stocks
Exposures Interest Rates US Equities
Teladoc Can’t Rely On Hype To Attract Investors
Via InvestorPlace
We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit
Via Investor's Business Daily
5 Cathie Wood Stocks to Buy in June
Via InvestorPlace
COVID-19 Vaccine Patent Waiver Expected Soon, Says WTO Head: Reuters
Via Benzinga
Breakthroughs In Treating Killer Diseases Could Lengthen Life
Via FinancialNewsMedia
Topics Death
Exposures Death
Morning Brief: Top Financial Stories Dominating on Monday, June 6
Via Benzinga
AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%
Via Benzinga
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease
From AstraZeneca
Via Business Wire
CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial
From AstraZeneca
Via Business Wire
Abbott Stock Looks To Emerge From Bear Market Stronger
Via Investor's Business Daily
First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
From AstraZeneca
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.